pravastatin has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, ML; Desai, P; Howard, BV; Manson, JE; Martin, LW; Ray, RM; Rohan, T; Safford, M; Simon, MS; Wallace, R; Wu, C | 1 |
| Brañes, J; Carvajal, J; Chen-Lin, K; Cuello, M; Gejman, R; Kato, S; Oliva, B; Owen, GI; Sadarangani, A; Smalley, S | 1 |
2 other study(ies) available for pravastatin and Cancer of Ovary
| Article | Year |
|---|---|
An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Carcinoma, Endometrioid; Carcinosarcoma; Endometrial Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Postmenopause; Pravastatin; Proportional Hazards Models; Risk Factors; United States; Women's Health | 2018 |
Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelium; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Mevalonic Acid; Ovarian Neoplasms; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes; Signal Transduction; Simvastatin; Uterine Cervical Neoplasms; Water | 2010 |